Validation and clinical application of a multiplex high performance liquid chromatography – tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections

Décosterd, Laurent A.; Mercier, Thomas; Ternon, Béatrice; Cruchon, Sandra; Guignard, Nicole; Lahrichi, S.; Pesse, Benoît; Rochat, Bertrand; Burger, Raphaël; Lamoth, Frédéric; Pagani, Jean‐Luc; Eggimann, Philippe; Csajka, Chantal; Choong, Eva; Buclin, Thierry; Widmer, Nicolas; André, Pascal; Marchetti, Olivier

doi:10.1016/j.jchromb.2020.122160

Cited by 46 publications

(78 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Common features for all methods is the use of protein precipitation using either methanol or acetonitrile and all methods used C18 LCcolumns for separation 14,15,27,28 . LC-MS separation and detection might not be able to avoid matrix effects 29 , but Decosterd et al 30 , reported that even with matrix effects at 165%, the use of ceftriaxone-13CD 3 stable isotope internal standard compensated fully for this matrix effect. This resulted in a normalized matrix factor of 101.7%, demonstrating the importance of using a suitable internal standard.…”

Section: Matrix Effectmentioning

confidence: 99%

“…The internal standard in this work did not show any matrix effects and can therefore do little to compensate for matrix effects affecting ceftriaxone. A more suitable stable isotope internal standard would have been desirable in this case, and would most likely have experienced the same matrix effect as ceftriaxone and therefore compensated for any potential differences in the signal 30 .…”

Section: Matrix Effectmentioning

confidence: 99%

See 1 more Smart Citation

Determination of ceftriaxone in human plasma using liquid chromatography–tandem mass spectrometry

et al. 2021

View full text Add to dashboard Cite

Ceftriaxone is a cephalosporin antibiotic drug used as first-line treatment for a number of bacterial diseases. Ceftriaxone belongs to the third generation of antibiotics and is available as an intramuscular or intravenous injection. Previously published pharmacokinetic studies have used high-performance liquid chromatography coupled with ultraviolet detection (HPLC-UV) for the quantification of ceftriaxone. This study aimed to develop and validate a bioanalytical method for the quantification of ceftriaxone in human plasma using liquid chromatography followed by tandem mass spectrometry (LC-MS/MS). Sample preparation was performed by protein precipitation of 100 µl plasma sample in combination with phospholipid-removal techniques to minimize matrix interferences. The chromatographic separation was performed on an Agilent Zorbax Eclipse Plus C18 column with 10 mM ammonium formate containing 2% formic acid: acetonitrile as mobile phase at a flow rate of 0.4 ml/min with a total run time of 10 minutes. Both the analyte and cefotaxime (internal standard) were quantified using the positive electrospray ionization (ESI) mode and selected reaction monitoring (SRM) for the precursor-product ion transitions m/z 555.0→396.1 for ceftriaxone and 456.0→324.0 for cefotaxime. The method was validated over the concentration range of 1.01-200 μg/ml. Calibration response showed good linearity (correlation coefficient > 0.99) and matrix effects were within the ±15% limit in 6 different lots of sodium heparin plasma tested. However, citrate phosphate dextrose plasma resulted in a clear matrix enhancement of 24% at the low concentration level, which was not compensated for by the internal standard. Different anticoagulants (EDTA, heparin and citrate phosphate dextrose) also showed differences in recovery. Thus, it is important to use the same anticoagulant in calibration curves and clinical samples for analysis. The intra-assay and inter-assay precision were less than 5% and 10%, respectively, and therefore well within standard regulatory acceptance criterion of ±15%.

show abstract

Section: Matrix Effectmentioning

confidence: 99%

Section: Matrix Effectmentioning

confidence: 99%

Determination of ceftriaxone in human plasma using liquid chromatography–tandem mass spectrometry

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Testing from dried blood spots (DBSs) is now possible for LSDs, making population screening technically feasible. α-Gal A and lyso-GL-3 analysis and GLA sequencing in DBS for the diagnosis of FD were evaluated [ 8 ]. α-Gal A activity testing is diagnostic for male patients.…”

Section: Introductionmentioning

confidence: 99%

Multidisciplinary approach to screening and management of children with Fabry disease: practice at a Tertiary Children’s Hospital in China

Shen

Liu

Jing

et al. 2021

Orphanet J Rare Dis

View full text Add to dashboard Cite

Background Fabry disease (FD) remains poorly recognized, especially in children in China. Considering the diversity and nonspecific clinical manifestations accompanying with life-threatening aspect of this disease, methods to improve effective screening and management of the suspects are needed. This study aims to explore how it can be done effectively from a multidisciplinary perspective for children with FD at a tertiary children’s hospital in China. Methods A multidisciplinary team (MDT) of pediatric FD experts was launched at Children’s Hospital of Fudan University. Children with high-risk characteristics were referred by the MDT screening team using the dried blood spot (DBS) triple-test (α-galactosidase A, globotriaosylsphingosine, GLA gene). For newborns who were undergoing genetic testing in the hospital, the GLA gene was listed as a routine analysis gene. Evaluation, family screening, and genetic counselling were implemented after screening by the MDT management team. Results Before the establishment of the MDT, no case was diagnosed with FD in the hospital. However, twelve months following the MDT program's implementation, thirty-five children with high-risk profiles were referred for screening by DBS triple-test, with a yield of diagnosis of 14.3% (5/35). These 5 diagnosed children were referred due to a high-risk profile of pain accompanied by dermatological angiokeratoma and hypohidrosis (n = 2), pain accompanied by abnormal liver function (n = 1), pain only (n = 1), and unexplained renal tubular dysfunction (n = 1). Two neonates were detected early with GLA mutations in the hospital, with a yield of detection of 0.14% (2/1420). Furthermore, another 3 children diagnosed with FD were referred from other hospitals. Family screening of these 10 diagnosed children indicated that 9 boys inherited it from their mothers and 1 girl inherited it from her father. Four of them started to receive enzyme replacement therapy. Conclusion Screening and management of children with FD is effective based on a defined screening protocol and a multidisciplinary approach. We should pay more attention to the high-risk profiles of pain, angiokeratoma, decreased sweating, and unexplained chronic kidney disease in children.

show abstract

“…HPLC-MS/MS is a very powerful tool and has many advantages, such as enhanced specificity and the ability to simultaneously measure multiple analytes in highly complex biological matrices [30]. In recent years, several HPLC-MS/MS papers have been published for the determination of various β-lactam antibiotics in human fluids [31][32][33][34][35][36][37]. The differences between them are, in addition to the conditions of analysis and validation parameters of the method, mainly in the following parameters: Sample pre-treatment method, sample volume, run time, total analyzing time, the number of ß-lactam antibiotics analyzed simultaneously, etc.…”

Section: Introductionmentioning

confidence: 99%

“…The differences between them are, in addition to the conditions of analysis and validation parameters of the method, mainly in the following parameters: Sample pre-treatment method, sample volume, run time, total analyzing time, the number of ß-lactam antibiotics analyzed simultaneously, etc. Some use either extraction methods such as SPE and LLE [34][35][36] or a simpler procedure based on protein precipitation [31][32][33]37] to pretreatment of the sample. The method used for pretreatment of the sample has a significant effect on the total analysis time.…”

Section: Introductionmentioning

confidence: 99%

A new HPLC‐MS/MS analytical method for quantification of tazobactam, piperacillin, and meropenem in human plasma

Krnáč¹,

Reiffová

Rolinski³

2021

J of Separation Science

View full text Add to dashboard Cite

A simple and fast high-performance liquid chromatography with tandem mass spectrometry method for quantification of tazobactam, piperacillin, and meropenem in human plasma has been developed and validated. Simple sample preparation with a volume of 10 μL was done by protein precipitation with a mixture of methanol-acetonitrile-water (6:2:2, v/v/v). Chromatographic separation was achieved on a Luna column with a precolumn security guard by gradient elution using a mobile phase consisting of water with the addition of 0.1% formic acid (component A) and mixture methanol-acetonitrile (8:2, v/v) with the addition of 0.1% formic acid (component B). The run time was 2.7 min. The lower limits of detection and lower limits of quantification were for piperacillin 0.03 and 0.1 mg/L, for meropenem 0.04 and 0.2 mg/L and for tazobactam 0.16 and 0.5 mg/L. The validated method was used for therapeutic monitoring of tazobactam, piperacillin, and meropenem in samples of patients treated in the intensive care unit.

show abstract

Validation and clinical application of a multiplex high performance liquid chromatography – tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections

Cited by 46 publications

References 39 publications

Determination of ceftriaxone in human plasma using liquid chromatography–tandem mass spectrometry

Determination of ceftriaxone in human plasma using liquid chromatography–tandem mass spectrometry

Multidisciplinary approach to screening and management of children with Fabry disease: practice at a Tertiary Children’s Hospital in China

A new HPLC‐MS/MS analytical method for quantification of tazobactam, piperacillin, and meropenem in human plasma

Contact Info

Product

Resources

About